Skip to main content

Oncology and Therapy

Ausgabe 1/2024

Inhalt (15 Artikel)

Open Access Editorial

From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa

Zodwa Dlamini, Thulo Molefi, Richard Khanyile, Mahlori Mkhabele, Botle Damane, Alexandre Kokoua, Meshack Bida, Kamal S. Saini, Nkhensani Chauke-Malinga, Thifhelimbilu Emmanuel Luvhengo, Rodney Hull

Open Access Editorial

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Heidi Ko, Rebecca A. Previs, Kyle C. Strickland, Jonathan Klein, Brian Caveney, Chiara Chiruzzi, Marcia Eisenberg, Eric A. Severson, Shakti Ramkissoon, Kamal S. Saini

Open Access Commentary

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?

Elisa Agostinetto, Luca Arecco, Evandro de Azambuja

Open Access Original Research

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio, Pasquale Pisapia, Gaia Goteri, Francesca Barbisan, Caterina Chiappetta, Angelina Pernazza, Domenico Campagna, Marco Giordano, Giuseppe Perrone, Giovanna Sabarese, Annalisa Altimari, Dario de Biase, Giovanni Tallini, Daniele Calistri, Elisa Chiadini, Laura Capelli, Alfredo Santinelli, Anna Elisa Gulini, Elisa Pierpaoli, Manuela Badiali, Stefania Murru, Riccardo Murgia, Elena Guerini Rocco, Konstantinos Venetis, Nicola Fusco, Denise Morotti, Andrea Gianatti, Daniela Furlan, Giulio Rossi, Laura Melocchi, Maria Russo, Caterina De Luca, Lucia Palumbo, Saverio Simonelli, Antonella Maffè, Paola Francia di Celle, Tiziana Venesio, Maria Scatolini, Enrico Grosso, Sara Orecchia, Matteo Fassan, Mariangela Balistreri, Elisabetta Zulato, Daniela Reghellin, Elena Lazzari, Maria Santacatterina, Maria Liliana Piredda, Manuela Riccardi, Licia Laurino, Elena Roz, Domenico Longo, Daniela Petronilla Romeo, Carmine Fazzari, Andrea Moreno-Manuel, Giuseppe Diego Puglia, Andrey D. Prjibelski, Daria Shafranskaya, Luisella Righi, Angela Listì, Domenico Vitale, Antonino Iaccarino, Umberto Malapelle, Giancarlo Troncone

Open Access Original Research

Experiences and Support Needs of Caregivers of Patients with Higher-Risk Myelodysplastic Syndrome via Online Bulletin Board in the USA, Canada and UK

Pauline Frank, Anne Olshan, Tracey Iraca, Cindy Anthony, Sophie Wintrich, Emma Sasse

Open Access Original Research

Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia

Dany Habr, Manmohan Singh, Roberto Uehara

Open Access Original Research

Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

Hong Chen, Yan Wen, Yun Zeng, Lie Lin, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Qiang Wang, Xuan Zhou, Xiaoli Liu, Hong Qu, Zhenfang Liu, Xin Du, Na Xu

Open Access Original Research

A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario

Giuseppe Di Lorenzo, Aieta Michele, Leo Silvana, Domenico Bilancia, Rossella Di Trolio, Michela Rosaria Iuliucci, Concetta Ingenito, Roberta Rubino, Arianna Piscosquito, Michele Caraglia, Marianna Donnarumma, Ferdinando Costabile, Raffaele Conca, Marco Pisino, Angelo Vaia, Luca Scafuri, Antonio Verde, Carlo Buonerba

Open Access Case Series

Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?

Umut Yılmaz, Selin Küçükyurt, Muhlis Cem Ar, Ahmet Emre Eşkazan

Open Access Case Report

Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi

Open Access Correction

Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer

Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi

Open Access Case Report

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Reyes Bernabé, Stephen V. Liu, Amparo Sánchez-Gastaldo, Miriam Alonso García

Open Access Case Report

Long Term Remission of Capillary Leak Syndrome Associated with Monoclonal Gammopathy with Progression to Multiple Myeloma After Autologous Stem Cell Transplantation: a Case Report and Review of the Literature

Gerardo Hermida, Rodolfo Alvarez-Nuño, Jesús San Miguel-Izquierdo, Santiago González-Quijada, Tomás José González-López

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.